Holen Sie sich die Stockscreener-App
25.48
0.08%
-0.02
Schlusskurs vom Vortag:
$25.50
Offen:
$25.55
24-Stunden-Volumen:
365.21K
Relative Volume:
0.73
Marktkapitalisierung:
$1.00B
Einnahmen:
$734.86M
Nettoeinkommen (Verlust:
$5.14M
KGV:
203.84
EPS:
0.125
Netto-Cashflow:
$132.71M
1W Leistung:
+0.35%
1M Leistung:
+8.80%
6M Leistung:
+8.29%
1J Leistung:
+7.56%
1-Tages-Spanne:
$24.90
$25.55
1-Wochen-Bereich:
$24.86
$26.66
52-Wochen-Spanne:
$18.80
$27.64
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
650-242-8052
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.48 | 1.00B | 734.86M | 5.14M | 132.71M | 0.125 |
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.56 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-25 | Hochstufung | Truist | Hold → Buy |
| 2025-01-30 | Hochstufung | Truist | Sell → Hold |
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Deals tracker: IKS Health acquires TruBridge in $557M deal - Modern Healthcare
Pacira BioSciences stock trades steady as pain-management pipeline stays in focus - ad-hoc-news.de
Understanding the Setup: (PCRX) and Scalable Risk - Stock Traders Daily
82P Forecast — Price Target — Prediction for 2027 - TradingView
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Pacira uses stock awards to recruit 10 new employees - Stock Titan
Pacira BioSciences (PCRX) Wins Broader EXPAREL Reimbursement, Is The Stock Still Undervalued? - Sahm
Zimmer Biomet acquires rights to medical device for $140 million - Inside INdiana Business
Enterprise value to revenue forward of Pacira Biosciences, Inc. – BX:82P - TradingView
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare - TradingView
Pacira to divest iovera business to Zimmer Biomet in up to $140M deal - MSN
UnitedHealthcare adds separate reimbursement for Exparel By Investing.com - Investing.com Australia
Sector Update: Healthcare - Moomoo
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal - TradingView
Pacira BioSciences to divest its iovera° business to Zimmer Biomet - Medical Buyer
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL - markets.businessinsider.com
Pacira BioSciences' Exparel Now Separately Reimbursed by UnitedHealthcare Across Outpatient Settings - marketscreener.com
PCRX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $38 - GuruFocus
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL® - The Manila Times
Zimmer Biomet to acquire iovera device from Pacira for $140m - Yahoo Finance
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Price to earnings forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Pacira BioSciences (PCRX) Sells iovera° Business to Zimmer Biome - GuruFocus
Zimmer Biomet Holdings, Inc. agreed to acquire iovera ° Business of Pacira BioSciences from Pacira BioSciences, Inc. for $140 million. - marketscreener.com
Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
Pacira Biosciences Announces Agreement to Div - Moomoo
Zimmer to buy Pacira pain relief device for up to $140M - MedTech Dive
Pacira divests iovera device to Zimmer Biomet for up to $140m - Investing.com
Pacira Biosciences Announces Agreement To Divest Its Iovera° Business To Zimmer Biomet - TradingView
Pacira BioSciences stock rises on Zimmer Biomet deal By Investing.com - Investing.com South Africa
Pacira BioSciences stock rises on Zimmer Biomet deal - Investing.com UK
Pacira BioSciences Divests CryoTech to Zimmer Biomet - TipRanks
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet - The Manila Times
Pacira BioSciences Sells iovera° Device to Zimmer Biomet in $140 Million Deal, Focuses on Biopharma Innovation - Minichart
Pacira BioSciences to Divest iovera° to Zimmer Biomet for Up to $140 Million - Quiver Quantitative
Pacira BioSciences to Sell Iovera Cryoanalgesia Business to Zimmer for Up to $140 Million - TradingView
Pacira (NASDAQ: PCRX) divests iovera° business to Zimmer Biomet for up to $140M - Stock Titan
Pacira offloads iovera° for up to $140M, keeps spasticity program - Stock Titan
Pacira Biosciencesto Use Upfront Proceeds - Moomoo
PCRX Forecast — Price Target — Prediction for 2027 - TradingView
Pacira Biosciences, Inc. Actuals & Estimates (NASDAQ:PCRX) - TradingView
Price to book forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Enterprise value to EBIT forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Enterprise value to EBIT forward of Pacira Biosciences, Inc. – FWB:82P - TradingView
Price to sales forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Enterprise value to revenue forward of Pacira Biosciences, Inc. – FWB:82P - TradingView
Pacira BioSciences, Inc.(NasdaqGS: PCRX) added to Russell 2000 Value-Defensive Index - marketscreener.com
Pacira BioSciences, Inc.(NasdaqGS: PCRX) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Price to earnings forward of Pacira Biosciences, Inc. – FWB:82P - TradingView
Price to sales forward of Pacira Biosciences, Inc. – FWB:82P - TradingView
The Technical Signals Behind (PCRX) That Institutions Follow - Stock Traders Daily
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.42%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):